Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor

Journal of Bone and Mineral Research

Volumn 26, Issue 10, 2011, Pages 2523-2536

  Clines, Gregory A ^a,b,c   Mohammad, Khalid S ^c,f   Grunda, Jessica M ^a   Clines, Katrina L ^a,c   Niewolna, Maria ^c,f   McKenna, C Ryan ^c   McKibbin, Christopher R ^c   Yanagisawa, Masashi ^d   Suva, Larry J ^e   Chirgwin, John M ^c,f   Guise, Theresa A ^c,f  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bone; endothelin A receptor; endothelin 1; osteoblast; sex steroids

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ENDOTHELIN A RECEPTOR;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REMODELING; CASTRATION; CELL DENSITY; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; FEMUR; HOMEOSTASIS; HYPOGONADISM; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PHENOTYPE; REGULATORY MECHANISM; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TIBIA; TRABECULAR BONE;

3T3 CELLS; ANIMALS; BASE SEQUENCE; BONE DEVELOPMENT; DNA PRIMERS; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; OSTEOBLASTS; POLYMERASE CHAIN REACTION; RECEPTOR, ENDOTHELIN A;

EID: 80053214622     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.450     Document Type: Article

References (47)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T,. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332 (6163): 411-5. (Pubitemid 18090241)
2. Clines GA, Guise TA,. Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med. 2008; 10: e7.
3. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW,. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995; 1 (9): 944-9.
4. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA,. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA. 2003; 100 (19): 10954-9. (Pubitemid 37140134)
5. Drake JM, Danke JR, Henry MD,. Bone-specific growth inhibition of prostate cancer metastasis by atrasentan. Cancer Biol Ther. 2010; 9 (8): 607-14.
6. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB, Atrasentan Phase SGI III., A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007; 110 (9): 1959-66. (Pubitemid 350036854)
7. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA,. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol. 2008; 55 (5): 1112-23.
8. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Juppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML,. The Osteoporosis-Pseudoglioma Syndrome Collaborative G. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107 (4): 513-23. (Pubitemid 33152786)
9. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP,. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346 (20): 1513-21. (Pubitemid 34755690)
10. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML,. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70 (1): 11-9. (Pubitemid 34031693)
11. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML, Williams BO,. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res. 2004; 19 (12): 2033-40. (Pubitemid 41103418)
12. Clines GA, Mohammad KS, Bao Y, Stephens O, Suva LJ, Shaughnessy JD, Fox JW, Chirgwin JM, Guise TA,. Dickkopf homologue 1 mediates endothelin-1- stimulated new bone formation. Mol Endocrinol. 2007; 22: 486-98. (Pubitemid 46184897)
13. Saless N, Litscher SJ, Franco GE, Houlihan MJ, Sudhakaran S, Raheem KA, O'Neil TK, Vanderby R, Demant P, Blank RD,. Quantitative trait loci for biomechanical performance and femoral geometry in an intercross of recombinant congenic mice: restriction of the Bmd7 candidate interval. FASEB J. 2009; 23 (7): 2142-54.
14. Van Sant C, Wang G, Anderson MG, Trask OJ, Lesniewski R, Semizarov D,. Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway. Mol Cancer Ther. 2007; 6 (1): 253-61. (Pubitemid 46206689)
15. Kozawa O, Kawamura H, Hatakeyama D, Matsuno H, Uematsu T,. Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts: involvement of p38 mitogen-activated protein kinase. Cellr Signalling. 2000; 12 (6): 375-80. (Pubitemid 30417600)
16. Kitten AM, Andrews CJ,. Endothelin-1 expression in long-term cultures of fetal rat calvarial osteoblasts: regulation by BMP-7. J Cell Physiol. 2001; 187 (2): 218-25. (Pubitemid 32270080)
17. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, Nagai R, Oda H, Kuwaki T, Cao WH, Kamada N., et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994; 368 (6473): 703-10. (Pubitemid 24153409)
18. Clouthier D, Hosoda K, Richardson J, Williams S, Yanagisawa H, Kuwaki T, Kumada M, Hammer R, Yanagisawa M,. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 1998; 125: 813-24. (Pubitemid 28142824)
19. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL,. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002; 277 (46): 44005-12. (Pubitemid 36157826)
20. Kedzierski RM, Grayburn PA, Kisanuki YY, Williams CS, Hammer RE, Richardson JA, Schneider MD, Yanagisawa M,. Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol. Mol Cell Biol. 2003; 23 (22): 8226-32. (Pubitemid 37377512)
21. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR,. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2 (6): 595-610.
22. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R,. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25 (7): 1468-86.
23. Suva LJ, Hartman E, Dilley JD, Russell S, Akel NS, Skinner RA, Hogue WR, Budde U, Varughese KI, Kanaji T, Ware J,. Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease. Am J Pathol. 2008; 172: 430-9. (Pubitemid 351282030)
24. Gasser JA., Bone measurements by peripheral quantitative computed tomography of rodents. In:, Helfirch MH, Ralston SH, eds. Bone research protocols. Totowa, NJ: Humana Press; 2003. pp 323-341.
25. Vedi S, Compston J., Bone histomorphometry. In:, Helfirch MH, Ralston SH, eds. Bone research protocols. Totowa, NJ: Human Press; 2003. pp 283-298.
26. van't Hof RJ., Osteoclast formation in the mouse coculture assay. In:, Helfrich MH, Ralston SH, eds. Methods in molecular medicine: bone research protocols. Totowa, NJ: Humana Press; 2003. pp 145-152.
27. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T,. Osteoblastic cells are involved in osteoclast formation. Endocrinology. 1988; 123 (5): 2600-2.
28. Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, Econs MJ, Karasik D, Devoto M, Kammerer CM, Spector T, Andrew T, Cupples LA, Duncan EL, Foroud T, Kiel DP, Koller D, Langdahl B, Mitchell BD, Peacock M, Recker R, Shen H, Sol-Church K, Spotila LD, Uitterlinden AG, Wilson SG, Kung AW, Ralston SH,. Meta-analysis of genome-wide scans provides evidence for sex- and site-specific regulation of bone mass. J Bone Miner Res. 2007; 22 (2): 173-83. (Pubitemid 46167787)
29. Yershov Y, Baldini TH, Villagomez S, Young T, Martin ML, Bockman RS, Peterson MG, Blank RD,. Bone strength and related traits in HcB/Dem recombinant congenic mice. J Bone Miner Res. 2001; 16 (6): 992-1003. (Pubitemid 32467143)
30. Judex S, Garman R, Squire M, Donahue LR, Rubin C,. Genetically based influences on the site-specific regulation of trabecular and cortical bone morphology. J Bone Miner Res. 2004; 19 (4): 600-6. (Pubitemid 41071220)
31. Klein RF, Turner RJ, Skinner LD, Vartanian KA, Serang M, Carlos AS, Shea M, Belknap JK, Orwoll ES,. Mapping quantitative trait loci that influence femoral cross-sectional area in mice. J Bone Miner Res. 2002; 17 (10): 1752-60.
32. Koller DL, Schriefer J, Sun Q, Shultz KL, Donahue LR, Rosen CJ, Foroud T, Beamer WG, Turner CH,. Genetic effects for femoral biomechanics, structure, and density in C57BL/6J and C3H/HeJ inbred mouse strains. J Bone Miner Res. 2003; 18 (10): 1758-65. (Pubitemid 37322552)
33. 2 and RI mice. J Bone Miner Res. 2006; 21 (8): 1267-75. (Pubitemid 44128340)
34. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D,. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005; 280 (20): 19883-7. (Pubitemid 41379516)
35. Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z,. Linking β-catenin to androgen-signaling pathway. J Biol Chem. 2002; 277 (13): 11336-44.
36. Singh R, Bhasin S, Braga M, Artaza JN, Pervin S, Taylor WE, Krishnan V, Sinha SK, Rajavashisth TB, Jasuja R,. Regulation of myogenic differentiation by androgens: cross-talk between androgen receptor/ beta-catenin and follistatin/transforming growth factor-β signaling pathways. Endocrinology. 2009; 150 (3): 1259-68.
37. Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, Levine AC,. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res. 2007; 67 (12): 5747-53. (Pubitemid 46985007)
38. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F,. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001; 16 (9): 1575-82. (Pubitemid 32786425)
39. Wang Y, Wan C, Deng L, Liu X, Cao X, Gilbert SR, Bouxsein ML, Faugere MC, Guldberg RE, Gerstenfeld LC, Haase VH, Johnson RS, Schipani E, Clemens TL,. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007; 117 (6): 1616-26. (Pubitemid 46871346)
40. Wan C, Gilbert SR, Wang Y, Cao X, Shen X, Ramaswamy G, Jacobsen KA, Alaql ZS, Eberhardt AW, Gerstenfeld LC, Einhorn TA, Deng L, Clemens TL,. Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci USA. 2008; 105 (2): 686-91. (Pubitemid 351171769)
41. Sharifi N, Gulley JL, Dahut WL,. Androgen deprivation therapy for prostate cancer. JAMA. 2005; 294 (2): 238-44. (Pubitemid 41043794)
42. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 352 (2): 154-64. (Pubitemid 40096612)
43. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J,. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006; 175 (1): 136-9. (Pubitemid 41797111)
44. Tanvetyanon T,. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005; 103 (2): 237-41. (Pubitemid 40129281)
45. Yee EF, White RE, Murata GH, Handanos C, Hoffman RM,. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med. 2007; 22 (9): 1305-10. (Pubitemid 47247311)
46. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G,. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346 (12): 896-903. (Pubitemid 34984638)
47. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ,. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46 (3): 529-35. (Pubitemid 41040298)